Conference
A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A NCI Canada clinical trials group study
Authors
Crump M; Leber B; Buckstein R; Kassis J; Matthews JH; Robinson S; Turner R; Hedley D; Petrenciuc O; McIntosh L
Volume
100
Pagination
pp. 267B-267B
Publisher
AMER SOC HEMATOLOGY
Publication Date
November 16, 2002
Name of conference
44th Annual Meeting of the American-Society-of-Hematology
Conference place
PHILADELPHIA, PENNSYLVANIA
Conference start date
December 6, 2002
Conference end date
December 10, 2002
Conference proceedings
BLOOD
Issue
11
ISSN
0006-4971